Comparison of Efficacy and Economic Value of Prandilin 25 and Humalog Mix 25 in Patients with Newly Diagnosed Type 2 Diabetes by a Continuous Glucose Monitoring System
ConclusionPrandilin 25 is non-inferior in clinical efficacy compared with Humalog mix 25. In view of the significant difference in the cost of the two kinds of insulin lispro 25, Prandilin 25 is a much more cost-effective anti-diabetes drug for management of T2DM.Trial RegistrationChinese Clinical Trial Register identifier, ChiCTR1800015829. (Source: Diabetes Therapy)
Source: Diabetes Therapy - September 22, 2018 Category: Endocrinology Source Type: research
A standardized approach based on dietary and multiple daily insulin injections for the management of diabetes in infants
In this study, the infants were fed at 3- to 4-h intervals. All patients were started on insulin therapy with 0.6 U/kg/day divided equally into four doses. The morning, noon, and evening doses were given as premixed insulin (25% insulin lispro and 75% insulin lispro protamin sulphate), while the night insulin dose was given as premixed or neutral protamin Hagedorn (NPH) insulin according to the feeding freque ncy during the night. Nine-point capillary blood glucose profiles, HbA1c, and anthropometric measurements were evaluated. The study had 15 infants diagnosed with neonatal diabetes (ND) or type 1 diabetes mellitus (T...
Source: International Journal of Diabetes in Developing Countries - September 1, 2018 Category: Endocrinology Source Type: research
Male Patients with Longstanding Type 2 Diabetes Have a Higher Incidence of Hypoglycemia Compared with Female Patients
ConclusionMale patients with longstanding T2D had a higher incidence of hypoglycemia than female patients during intensive insulin therapy.Trial registrationClinicalTrials.gov identifier, ChiCTR-IPR-15007340. (Source: Diabetes Therapy)
Source: Diabetes Therapy - August 22, 2018 Category: Endocrinology Source Type: research
Formulary Considerations for Insulins Approved Through the 505(b)(2) "Follow-on" Pathway.
CONCLUSIONS: Follow-on insulin products approved through the 505(b)(2) pathway are supported by robust efficacy and safety data. As new follow-on insulins are approved and the regulatory change that will occur with these products in 2020 approaches, formulary decisions and clinical policies (eg, substitution) will continue to be revisited.
PMID: 30122087 [PubMed - as supplied by publisher] (Source: The Annals of Pharmacotherapy)
Source: The Annals of Pharmacotherapy - August 20, 2018 Category: Drugs & Pharmacology Authors: Rasmussen JT, Ipema HJ Tags: Ann Pharmacother Source Type: research
Effects of Insulin Treatment with Glargine or Premixed Insulin Lispro Programs in Type 2 Diabetes Mellitus Patients: A Meta-analysis of Randomized Clinical Trials
Diabetes Technology&Therapeutics, Ahead of Print. (Source: Diabetes Technology and Therapeutics)
Source: Diabetes Technology and Therapeutics - August 10, 2018 Category: Endocrinology Authors: Di Sun Xu Zhang Xiu-xin Hou Source Type: research
Effects of Insulin Treatment with Glargine or Premixed Insulin Lispro Programs in Type 2 Diabetes Mellitus Patients: A Meta-analysis of Randomized Clinical Trials
Diabetes Technology&Therapeutics, Ahead of Print. (Source: Diabetes Technology)
Source: Diabetes Technology - August 10, 2018 Category: Endocrinology Authors: Di Sun Xu Zhang Xiu-xin Hou Source Type: research
Ultra ‐rapid BioChaperone Lispro improves postprandial blood glucose excursions vs insulin lispro in a 14‐day crossover treatment study in people with type 1 diabetes
Diabetes, Obesity and Metabolism, EarlyView. (Source: Diabetes, Obesity and Metabolism)
Source: Diabetes, Obesity and Metabolism - July 13, 2018 Category: Endocrinology Authors: Grit
Andersen
MD
,
Gr égory
Meiffren
PhD
,
Daniela
Lamers
PhD
,
J. Hans
DeVries
MD
,
Aymeric
Ranson
MSc
,
Cyril
Seroussi
MSc
,
Bertrand
Alluis
PhD
,
Martin
Gaudier
PhD
,
Olivier
Soula
PhD
,
Tim
Heise
MD Source Type: research
Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial
This study is registered with ClinicalTrials.gov, number NCT01621178.FindingsBetween Aug 15, 2012, and Nov 30, 2015, 577 patients were randomly assigned, 193 to dulaglutide 1·5 mg, 190 to dulaglutide 0·75 mg, and 194 to insulin glargine. The effects on HbA1c change at 26 weeks of dulaglutide 1·5 mg and 0·75 mg were non-inferior to those of insulin glargine (least squares mean [LSM] −1·2% [SE 0·1] with dulaglutide 1·5 mg [183 patients]; −1·1% [0·1] with dulaglutide 0·75 mg [180 patients]; −1·1% [0·1] with insulin glargine [186 patients]; one-sided p≤0·0001 for both dulaglutide doses vs insulin glargine)...
Source: The Lancet Diabetes and Endocrinology - July 10, 2018 Category: Endocrinology Source Type: research
Contribution of BHG and PPHG to Overall Hyperglycemia in T2DM Patients Treated with LM25 and LM50: Post Hoc Analysis of a Randomized Crossover Trial
ConclusionsFor T2DM patients treated with premixed insulin analogues, postprandial hyperglycemia played a major role in the subgroup of patients with HbA1c < 8.5%, while fasting hyperglycemia became the major contributor to overall hyperglycemia in the subgroup of patients with HbA1c ≥ 8.5%.Trial RegistrationChinese Clinical Trial Registry Identifier ChiCTR-TTRCC-12002516.FundingLilly Suzhou Pharmaceutical Co., Ltd. (Shanghai Branch, China) and National Key Program of Clinical Science of China (WBYZ2011-873). (Source: Diabetes Therapy)
Source: Diabetes Therapy - June 27, 2018 Category: Endocrinology Source Type: research
Ultra ‐rapid BioChaperone Lispro Improves post‐prandial Blood Glucose Excursions versus Insulin Lispro in a 14‐day crossover Treatment Study in Patients with Type 1 Diabetes
Diabetes, Obesity and Metabolism,Volume 0, Issue ja, -Not available-. (Source: Diabetes, Obesity and Metabolism)
Source: Diabetes, Obesity and Metabolism - June 20, 2018 Category: Endocrinology Authors: Grit
Andersen
,
Gr égory
Meiffren
,
Daniela
Lamers
,
J. Hans
DeVries
,
Aymeric
Ranson
,
Cyril
Seroussi
,
Bertrand
Alluis
,
Martin
Gaudier
,
Olivier
Soula
,
Tim
Heise Source Type: research
Performance of a 2-step insulin infusion protocol with adjustment of insulin doses for Asians in the medical intensive care unit following cardiothoracic surgery
ConclusionsOur insulin infusion protocol seems to be efficacious, safe, and widely feasible for Asian patients because of its simplicity and lower insulin dose. (Source: Diabetology International)
Source: Diabetology International - June 15, 2018 Category: Endocrinology Source Type: research
Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial
This study is registered with ClinicalTrials.gov, number NCT01621178. Findings Between Aug 15, 2012, and Nov 30, 2015, 577 patients were randomly assigned, 193 to dulaglutide 1·5 mg, 190 to dulaglutide 0·75 mg, and 194 to insulin glargine. The effects on HbA1c change at 26 weeks of dulaglutide 1·5 mg and 0·75 mg were non-inferior to those of insulin glargine (least squares mean [LSM] −1·2% [SE 0·1] with dulaglutide 1·5 mg [183 patients]; −1·1% [0·1] with dulaglutide 0·75 mg [180 patients]; −1·1% [0·1] with insulin glargine [186 patients]; one-sided p≤0·0001 for both dulaglutide doses vs insulin glargi...
Source: The Lancet Diabetes and Endocrinology - June 15, 2018 Category: Endocrinology Source Type: research
In Brief: Another Insulin Lispro (Admelog) for Diabetes (online only)
Date: June 18, 2018
Issue #:
1549Summary:
The FDA has approvedAdmelog (Sanofi-Aventis), an insulin lispro product similar toHumalog (Lilly), which went off patent in 2013.Approval ofAdmelog was based on efficacy data withHumalog and on two 6-month, open-label, randomized, noninferiority trials. In SORELLA 11 in 507 patients with type 1 diabetes and SORELLA 22 in 505 patients with type 2 diabetes,Admelog was noninferior toHumalog in lowering A1C, fasting plasma glucose levels, and self-monitored plasma glucose levels. The incidence of adverse effects, including hypoglycemia, was s...
Source: The Medical Letter - June 11, 2018 Category: Drugs & Pharmacology Authors: admin Source Type: research
Identification of N-Terminally Truncated Derivatives of Insulin Analogs Formed in Pharmaceutical Formulations
ConclusionsThe following derivatives formed by truncation of the B chain in insulin analogs were identified in pharmaceutical formulations: desPheB1-N-formyl-ValB2 derivative, desPheB1 derivative, pyroGluB4 derivative. (Source: Pharmaceutical Research)
Source: Pharmaceutical Research - May 16, 2018 Category: Drugs & Pharmacology Source Type: research
